中证报中证网讯(王珞)针对近期流感病毒活动水平呈现上升态势，南新制药对中国证券报表示，在此轮 防控流感中，公司依托在感冒与抗病毒药物领域积累的技术优势，全力保障相关治疗药物的生产与供 应，以全维产品矩阵发力流感防控。 资料显示，作为一家专注于抗流感病毒药物及其他重大疾病领域药品研发、生产与销售的创新药企，南 新制药已建立起从注射到口服、从治疗到预防的完整抗流感产品矩阵，产品横跨抗流感病毒感染、抗细 菌感染与解热镇痛三大核心治疗领域。 根据国家卫健委与国家中医药管理局联合发布的《流行性感冒诊疗方案(2025年版)》，神经氨酸酶抑制 剂类药物被列为流感治疗的核心选择。南新制药的帕拉米韦氯化钠注射液即为该类药物的典型代表。作 为国内首个获批上市的1.1类抗流感创新药，该产品曾获国家"重大新药创制"科技专项支持，被多版 《流行性感冒诊疗方案》列为推荐抗流感病毒注射用药。 与此同时，《2025抗流行性感冒病毒药物合理使用专家共识》指出，儿童与老年人用药需特别关注剂型 适配性。 公司相关负责人介绍，南新制药的磷酸奥司他韦干混悬剂适合低龄儿童与老年患者服用，进一步完善了 公司在抗流感领域的产品梯队。 在创新剂型方面，南新制 ...

Core Viewpoint - Recently, Lai Mei Pharmaceutical, a subsidiary of Zhongheng Group, successfully won bids for multiple core products in national and Guangdong alliance drug procurement, showcasing the company's market competitiveness and laying a solid foundation for future market expansion [1][2] Group 1: National Drug Procurement - Lai Mei Pharmaceutical's Nicorandil tablets (5mg) were selected in the 11th batch of national drug centralized procurement, marking a significant entry into the mainstream medical market by 2025 [1] - The selection of Nicorandil tablets will provide strong support for sales and meet broader clinical needs, injecting new momentum into Lai Mei Pharmaceutical's high-quality development [1] Group 2: Guangdong Alliance Drug Procurement - Lai Mei Pharmaceutical achieved success in multiple rounds of Guangdong alliance drug procurement, with selected products covering various fields including anti-infective drugs, specialty medications, and basic infusion solutions [1] - The successful procurement results for drugs like Clindamycin injection and Triptorelin acetate injection further demonstrate the company's strong performance in the market [1] - In the procurement for common and chronic disease medications, Lai Mei Pharmaceutical's Cefoperazone dry suspension (50mg) was also successfully selected, enhancing drug accessibility [2] Group 3: Company Strength and Market Impact - The dual breakthroughs in national and provincial procurement reflect Lai Mei Pharmaceutical's comprehensive strength [2] - The selection of multiple products in centralized procurement accelerates the clinical accessibility of quality drugs, benefiting a wider patient population and reinforcing the company's brand influence in niche markets [2]